Patrick Gunning & Diana Kraskouskaya win the RBC Prize for Innovation and Entrepreneurship for Dalriada Therapeutics at the Entrepreneurship Week Startup Showcase 2017.

April 3, 2017


A novel therapeutic that has been shown in advanced pre-clinical studies to target cancer without the toxic side effects of treatments like chemotherapy has earned the Gunning Group the top prize in a new business pitch competition. Established to reward and accelerate U of T’s innovative technologies and start-ups, the RBC Prize for Innovation and Entrepreneurship was presented to Dalriada Therapeutics, a company co-founded by Professor Gunning. He and his team plan to use the $25,000 prize to further investigate the potential applications of the therapeutic, called DT1, on a range of cancers, including acute myeloid leukemia and glioblastoma, an aggressive, hard-to-treat cancer that begins within the brain.

 

Please reload

Featured Posts

Congrats Murtaza on Publishing the Tetris-based approach to targeting HDAC8

July 30, 2020

1/3
Please reload

Recent Posts
Please reload

Archive
Please reload

Search By Tags

I'm busy working on my blog posts. Watch this space!

Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

UNIVERSITY OF TORONTO MISSISSAUGA

GUNNING GROUP © 2020

CONTACT US

  • White LinkedIn Icon
  • White Twitter Icon